Dxcover Announces Expansion of Its Leadership Team to Support Advancement of its Multi-Cancer Liquid Biopsy Platform

• Ron Andrews Joins Company as Non-Executive Chair
• Stacy Chick Named US Commercial & Business Development Advisor and Stuart McRoberts Named Commercial Director as Company Builds Out Its Commercial Team for US and Europe

GLASGOW, Scotland--(BUSINESS WIRE)-- Dxcover Limited, a clinical-stage diagnostics company pioneering Multi-Omic Spectral Analysis for early detection of multiple cancers, today announced it has named Ron Andrews as its Non-Executive Chair. Under his guidance, he will support the company’s business operations and long-term objectives, focusing on strategy, performance, and value creation.

Andrews brings more than three decades of experience in the diagnostic space in various senior commercialization roles. He most recently served as president and CEO of Oncocyte, where he led the transformation of the company from a blood-based testing research company to one with a portfolio of diagnostics for treatment decisions and blood-based monitoring in oncology and transplant, raising more than $100M. Prior to that he held leadership positions at The Bethesda Group, Thermo Fisher Scientific, GE, Roche Diagnostics, Abbott Diagnostics, amongst others. He is also a board member of the American Society of Clinical Oncologists (ASCO).

“Ron is a bona fide diagnostics leader, and his depth of experience will help Dxcover fulfill its mission in changing the way the industry approaches cancer diagnostics,” said Mark Hegarty, Ph.D., CEO, Dxcover. “Ron is joining the company at a very exciting time of growth as we continue the development of our platform and our leadership team.”

“I was drawn to Dxcover due to its unique platform leveraging Multi-Omic Spectral Analysis, as well as its mission to democratize access to care and deliver treatment to those who need it the most. I believe Dxcover is poised for rapid growth and am looking forward to working with this strong leadership team in the next phase of its journey,” says Andrews.

The company also announces the expansion of its commercial team with the appointment of Stacy Chick as US Commercial & Business Development Advisor and Stuart McRoberts as Commercial Director. Chick brings diagnostic and pharmaceutical commercialization experience as former CCO at Inivata and progressive leadership roles at Sanofi and BMS. She will be responsible for commercial and business development in the US. McRoberts has extensive In Vitro Diagnostics leadership experience, most recently as Senior Director of Business Development in the Clinical Diagnostics Division, Specialty Diagnostics Group of Thermo Fisher Scientific, and previously as General Manager (Region Europe) at Abbott Point of Care, Abbott Laboratories. He will lead the development of the global commercial strategy for the Dxcover Platform

Dxcover’s novel platform utilizes infrared spectroscopy and AI algorithms to provide Multi-Omic Spectral Analysis of blood serum. In 2022 Dxcover demonstrated enhanced ability to detect Stage I and Stage II tumors in eight cancers. In 2023 the company is advancing its test for Brain Cancer through multi-center European studies to obtain CEIVDR approval and is also embarking on a major prospective study in Colorectal Cancer and Advanced Adenoma.

About Dxcover Limited

Dxcover is a clinical stage liquid biopsy company developing tests for the early detection of multiple cancers, when treatment has a better chance to impact outcomes. The company has pioneered Multi-Omic Spectral Analysis for the early detection of cancer by infrared spectroscopy and has generated compelling clinical data with high accuracy detection of Stage I and Stage II cancers and adenomas. Dxcover is based in Scotland, United Kingdom and is expanding its network in Europe and the USA.

For further information go to https://www.dxcover.com/science

View source version on businesswire.com: https://www.businesswire.com/news/home/20230906107023/en/